免疫检查点的相关药物与疾病研究进展  

Advances in Immune Checkpoint Related Drugs and Diseases

作　　者：严国银 李军[1] YAN Guoyin;LI Jun(Key Laboratory of Tropical Biological Resources of Ministry of Education,School of Pharmacy,Hainan University,Haikou 570228,China)

机构地区：[1]海南大学药学院,热带生物资源教育部重点实验室,海口570228

出　　处：《中国药学杂志》2024年第6期469-475,共7页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金项目资助(31560261);海南省重点研发项目资助(ZDYF2020155);中国药学会-以岭生物医药创新基金项目资助(CPAYLJ201902);海南省自然科学基金项目资助(818MS039)。

摘　　要：免疫检查点(immune checkpoints, ICs)是免疫治疗的核心。由于ICs治疗具有靶向性强、长效性、患者耐受性好等优点,成为恶性肿瘤等一些重大疾病的治疗热点。笔者总结了近年来免疫共抑制受体、免疫共刺激受体的表达及免疫机制,列出了已批准上市以ICs为靶点类药物和以ICs为靶点药物临床研究数据。概括了ICs在癌症、病毒感染、自身免疫性疾病治疗中的探索。为以后ICs及相关药物的研究提供参考。Immune checkpoints(ICs)are the core of immunotherapy.Due to the advantages of strong targeting,long-term efficacy and good patient tolerance,immune checkpoint therapy has become a hot spot for the treatment of some major diseases such as malignant tumors.In this paper,the expression and immune mechanism of immunosuppression receptors and immunostimulatory receptors in recent years are summarized,and list the clinical research data of approved drugs targeting immune checkpoint is listed.It provides reference for future research of immune checkpoint and related drugs.

关 键 词：免疫检查点 靶点药物 免疫相关不良事件 

分 类 号：R730.51[医药卫生—肿瘤]